Free Trial
The Market Does Not Wait. MarketBeat All Access Alerts for $149
Get the Alerts
Claim MarketBeat All Access Sale Promotion

Guggenheim's Rating of Rapport Therapeutics on 10/20/2026

On October 20, 2026, Guggenheim updated its outlook on Rapport Therapeutics (NASDAQ:RAPP) with the action "Boost Price Target", setting a price target of $70.00. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Guggenheim

DateCompanyAction
10/22/2026
Elevance Health, Inc. stock logo
ELV
Elevance Health
Set Price Target
10/22/2026
NIKE, Inc. stock logo
NKE
NIKE
Reiterated Rating
10/22/2026
Meta Platforms, Inc. stock logo
META
Meta Platforms
Reiterated Rating
10/21/2026
Microsoft Corporation stock logo
MSFT
Microsoft
Reiterated Rating
10/21/2026
Northrop Grumman Corporation stock logo
NOC
Northrop Grumman
Boost Price Target
10/21/2026
GE Aerospace stock logo
GE
GE Aerospace
Set Price Target
More Ratings From Guggenheim